Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Role of EMpagliflozin on the Rate of Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-blind Placebo-controlled Randomized Clinical Trial

NCT06124937 is registered in ClinicalTrials.gov with Rajaie Cardiovascular Medical and Research Center as lead sponsor.

NCT NCT06124937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06124937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Role of EMpagliflozin on the Rate of Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-blind Placebo-controlled Randomized Clinical Trial
Lead sponsor
Rajaie Cardiovascular Medical and Research Center
Phase
Phase 3
Overall status
Unknown status
Start date
November 7, 2023
Completion date
December 30, 2024
Enrollment
492 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cabg, post-operative atrial fibrillation